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Betulinic acid enhances TGF-β signaling by
altering TGF-β receptors partitioning
between lipid-raft/caveolae and non-
caveolae membrane microdomains in mink
lung epithelial cells
C. L. Chen1,2,5*, C. Y. Chen1, Y. P. Chen1, Y. B. Huang1,3,5, M. W. Lin3,5, D. C. Wu4,5, H. T. Huang1,6, M. Y. Liu7,
H. W. Chang1, Y. C. Kao1 and P. H. Yang1
Abstract
Background: TGF-β is a key modulator in the regulation of cell proliferation and migration, and is also involved in
the process of cancer development and progression. Previous studies have indicated that TGF-β responsiveness is
determined by TGF-β receptor partitioning between lipid raft/caveolae-mediated and clathrin-mediated endocytosis.
Lipid raft/caveolae-mediated endocytosis facilitates TGF-β degradation and thus suppressing TGF-β responsiveness. By
contrast, clathrin-mediated endocytosis results in Smad2/3-dependent endosomal signaling, thereby promoting TGF-β
responsiveness. Because betulinic acid shares a similar chemical structure with cholesterol and has been reported to
insert into the plasma membrane, we speculate that betulinic acid changes the fluidity of the plasma membrane and
modulates the signaling pathway associated with membrane microdomains. We propose that betulinic acid modulates
TGF-β responsiveness by changing the partitioning of TGF-β receptor between lipid-raft/caveolae and non-caveolae
microdomain on plasma membrane.
Methods: We employed sucrose-density gradient ultracentrifugation and confocal microscopy to determine membrane
localization of TGF-β receptors and used a luciferase assay to examine the effects of betulinic acid in TGF-β-stimulated
promoter activation. In addition, we perform western blotting to test TGF-β-induced Smad2 phosphorylation and
fibronectin production.
Results and conclusions: Betulinic acid induces translocation of TGF-β receptors from lipid raft/caveolae to non-caveolae
microdomains without changing total level of TGF-β receptors. The betulinic acid-induced TGF-β receptors translocation
is rapid and correlate with the TGF-β-induced PAI-1 reporter gene activation and growth inhibition in Mv1Lu cells.
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Background
Betulinic acid (BetA) [1] is a luphane-type pentacyclic tri-
terpenoid (Fig. 1) of plant origin that is wildly distributed
in the outer bark of various tree species (eg, white-barked
birch trees). BetA exhibits diverse biological activities, and
antiviral, antibacterial, antioxidant, anti-inflammatory,
antifibrotic, and anticancer properties [2, 3]. Antitumori-
genesis is one of the most promising functions of BetA.
Previous reports have indicated that BetA induces
apoptosis in colorectal (DLD-1), breast (MCF7), pros-
tate (PC-3), and lung (A549) cancer cells via the mito-
chondrial pathway [4–6]. In addition, past studies have
reported that BetA-induced apoptosis is not associated
with the activation of ligand/receptor systems such as
CD95, and does not involve p53 [1]. In BetA-induced
apoptosis, the perturbation of mitochondrial function
(eg, loss of mitochondrial permeability transition and
the production of reactive oxygen species) precedes
other key features of apoptosis such as the activation of
the caspase cascade and nuclear fragmentation [7, 8].
Recent studies have indicated that BetA also modulate
signaling through members of the TGF-β superfamily,
which regulates inflammatory and immune responses,
cell growth, differentiation, and apoptosis [9, 10]. How-
ever, the underlying mechanisms regarding the effects
of BetA in TGF-β signaling are poorly understood.
TGF-β is a family of 25-kDa disulfide-linked dimeric
proteins. It has 3 members in mammals (TGF-β1, TGF-β2,
and TGF-β3,), which share approximately 70 % of the se-
quence homology [11, 12]. TGF-β exhibits bifunctional
growth regulation; it inhibits the growth of most cell
types, including epithelial cells, endothelial cells, and lym-
phocytes, and stimulates the proliferation of mesenchymal
cells such as fibroblasts [11, 12]. In epithelial cells, TGF-β
inhibits cell proliferation, induces apoptosis, and mediates
differentiation, implying that this signaling pathway en-
gages in tumor-suppressing activities in epithelial tumors
[13, 14]. However, TGF-β promotes invasive and meta-
static activities in late-stage tumor progression, implying
that TGF-β can paradoxically play opposing roles in
human cancers, and this is seemingly dependent on the
cancer stage. In addition to its growth regulatory activities,
TGF-β exhibits other biological activities, including the
regulation of extracellular matrix synthesis, chemotaxis,
angiogenesis, and the differentiation of several cell line-
ages. It has been implicated in numerous pathophysio-
logical processes including wound repair, tissue fibrosis,
immunosuppression, and morphogenesis [15]. The pri-
mary biological activities of TGF-β are mediated by spe-
cific cell surface receptors type I and type II (TβR-I and
TβR-II, respectively). TGF-β exerts its effects on cells by
binding to TβR-II, which induces the recruitment of TβR-
I with the subsequent activation of the receptor complex.
Smad2 and Smad3 are the direct substrates of the acti-
vated TGF-β receptor complex. After stimulation, the
Smad complex translocates into the nucleus, where it
functions as a member of different transcription factor
complexes that regulate the expression of various genes
[12, 13, 16].
We have previously reported that suppressed TGF-β re-
sponsiveness in the aortic endothelium plays a critical role
in the pathogenesis of atherosclerosis in hypercholesterol-
emic animals [17, 18]. A high concentration of cholesterol
in the culture medium suppresses TGF-β responsiveness
in cultured cells, including in endothelial cells, by indu-
cing the accumulation of cell-surface TGF-β-TGF-β re-
ceptor complexes in the lipid rafts/caveolae of the plasma
membrane, facilitating the rapid degradation of these
Fig. 1 Structure of betulinic acid (BetA)
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complexes, thereby attenuating TGF-β-stimulated signal-
ing and related responses [17–19]. This effect of choles-
terol is believed to be mediated by the increasing
formation or stabilization of the lipid rafts/caveolae, pre-
sumably through the direct insertion of cholesterol into
the plasma membranes of target cells [17, 18]. Lipid raft/
caveolae are thought to form platforms collecting assem-
blies of proteins involved in many key cellular functions,
including signal transduction, membrane fusion, cytoskel-
eton organization, lipid sorting, protein trafficking, and
the localization and activities of specific membrane chan-
nels [20–22]. Because BetA shares a similar chemical
structure with cholesterol, and was reported to insert into
the plasma membrane [23], it is rational to speculate that
BetA changes the fluidity of the plasma membrane and
modulates the signaling pathway associated with mem-
brane microdomains. We speculate that BetA modulates
TGF-β responsiveness by changing the partitioning of the
TGF-β receptor between the microdomains of the lipid
raft/caveolae and non-caveolae on the plasma membrane.
Because the TGF-β signaling pathway is a key medi-
ator that controls proliferation and inflammation, and
BetA has antitumor and anti-inflammation properties,
this study investigates the effect of BetA on TGF-β sig-
naling, and we attempt to elucidate the mechanisms
involved. We found that BetA activates TGF-β receptors
by moving them from lipid raft to non-raft membrane
microdomains, as perceived by the enhancement in
TGF-β-specific reporter gene activity, sucrose gradient
fractionation of the plasma membrane, fibronectin pro-
tein levels, Smad2/3 phosphorylation, nuclear transloca-
tion, and TGF-β-induced growth inhibition.
Methods
Materials
Dulbecco’s modified Eagle's medium (DMEM), phenyl-
methanesulfonyl fluoride (PMSF), Betulinic acid [(3b)-3-
hydroxy-lup-20(29)-en-28-oic acid], bovine serum albumin
(BSA), and peroxidase-conjugated anti-rabbit IgG were ob-
tained from Sigma (St. Louis, MO). The pre-stained pro-
tein ladder (64, 49, 37, 26, and 20 kDa) and fetal calf serum
(FCS) was obtained from Invitrogen (Carlsbad, CA). TGF-
β1 was purchased from Austral Biologicals (San Ramon,
CA). The polyclonal antibodies against early endosome
antigen 1 (EEA1), transferrin receptor (TfR), Smad2/3,
Caveolin-1, flotillin-2, epidermal growth factor receptor
(EGFR), TβR-I, TβR-II, and HA-probe were obtained from
Santa Cruz (Santa Cruz, CA). The rabbit polyclonal anti-
body to phospho-Smad2 was purchased from Cell Signal-
ing (Boston, MA).
Cell culture
Mink lung epithelial (Mv1Lu) cells and Mv1Lu cell stably
express plasminogen activator inhibitor-1 (PAI-1) luciferase
promoter were kindly provided by Dr. Jung San Huang
(Saint Louis University, Saint Louis, MO). The Mv1Lu cells
were cultured in DMEM supplemented with 10 % FCS, 1 %
penicillin, and streptomycin (pH 7.4). The cells were seeded
in tissue culture plates (Falcon, Bedford, MA, USA) and
incubated at 37 °C in a humidified atmosphere of 5 % CO2.
The Mv1Lu cells were subcultured twice per week through
trypsinization in a 0.25 % trypsin-EDTA solution after
washing with Ca2+-Mg2+-free saline.
Treatment of Mv1Lu cells with TGF-β after preincubation
with BetA
The Mv1Lu cells were grown in 12-well plastic plates
(4 × 105 cells/mL with 1 mL/well 10 % FCS-DMEM) for
24 h in a humidified CO2 incubator at 37 °C. Afterward,
the medium was replaced with fresh 1 % FCS-DMEM.
The cells were subsequently preincubated with BetA for
1 h at 37 °C. Next, TGF-β was added to the medium,
and incubation continued for an additional 48 h; the cul-
tures were then washed twice with cold PBS, and har-
vested for Western blot analysis. To observe Smad2/3
phosphorylation, the cells in the 12-well plastic plates
were preincubated with BetA for 1 h at 37 °C. Afterward,
TGF-β1 was added to the medium, and incubation con-
tinued for 30 min.
Western blot analysis
The cell lysates of Mv1Lu cells (approximately 50 μg
protein) were subjected to 10 % SDS-PAGE under redu-
cing conditions, and then electrotransferred to PVDF
membranes. After being incubated with 5 % nonfat milk
in Tris-buffered saline plus Tween 20 (TBST) (50 mM
Tris–HCl, pH 8.0, 150 mM NaCl, and 0.05 % Tween 20)
for 1 h at room temperature, the membranes were incu-
bated further with specific polyclonal antibodies to TβR-
I and TβR-II in TBST/non-fat milk at 4 °C for 18 h, and
washed 3 times with TBST for 10 min each. The bound
antibodies were detected using peroxidase-conjugated
anti-rabbit IgG and visualized using the ECL system
(ImageQuant).
Luciferase activity assay
The Mv1Lu cells were transiently transfected with fi-
bronectin [24] and collagen [25] luciferase promoter
plasmids through electroporation. The cell suspension
was mixed with 14 μg/mL of plasmid DNA (and renilla
control plasmid) before it was transferred into an elec-
troporation cuvette (0.4 cm gap, Bio-Rad, Hercules,
CA) and pulsed (950 μF, 250 V, Gene Pulser II, Bio-
Rad). After electroporation, the cells were seeded in 24-
well cluster plates (Corning), and growth continued for
an additional 24 h. The Mv1Lu cells stably express
luciferase reporter gene driven by the PAI-1 promoter
(MLECs – Clone 32), grown to near confluence on 24-




Fig. 2 (See legend on next page.)
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well plates, were treated with different concentrations
of BetA, with or without varying concentrations of
cholesterol at 37 °C for 1 h. The treated cells were fur-
ther incubated with 50 pM TGF-β1 at 37 °C for 6 h,
and lysed in 100 μL of a lysis buffer (Promega). The cell
lysates (approximately 20 μg of protein) were then
mixed with a D-luciferin (Gold Biotechnology, St. Louis,
MO) assay buffer and assayed using the luminometer
(Titertek-Berthold, Pforzheim, Germany). The luciferase
count was corrected for renilla activity, and a relative
increase in corrected luciferase count was calculated ver-
sus the controls. A constitutively active ALK-5 (caALK-5)
construct was cotransfected at a concentration of 1.2 μg/
mL in the indicated experiments.
Immunofluorescent detection of Smad2/3
Cells were grown on 24-mm round coverglass (Paul
Marienfeld). After 1 h of serum starvation and 1 h of
pretreatment with 5 μg/mL of BetA or the vehicle, cells
were stimulated with TGF-β1 (20 pM) for 30 min. They
were then washed with phosphate buffered saline (PBS)
and fixed in cold methanol for 15 min. Afterward, the
cells were blocked with 5 % goat serum (Dako) in 1 %
BSA/PBS. After incubation with mouse-anti-Smad2/3
(H-2; Santa Cruz Biotechnology) at 1:100 dilution in 1 %
BSA/PBS for 18 h at 4 °C, the cells were incubated with
donkey anti-mouse-FITC (Gene Tex) at room temperature
for 1 h. The coverglass was mounted with a slow-fade gold
antifade reagent and DAPI (Invitrogen). Photomicrographs
were taken using a Zeiss Axio Observer Z1 microscope
equipped with a Photometrics HQ2 camera.
Immunofluorescent confocal microscopy
The Mv1Lu cells were placed in a 24-mm coverglass and
transiently transfected with TβR-II-HA plasmid (0.4 μg)
by using lipofectamin 2000 (Invitrogen) in accordance to
the manufacturer protocol. The transfected cells were pre-
treated with 5 μg/mL of BetA at 37 °C for 1 h, and then
incubated with 100 pM of TGF-β1 for 30 min. After TGF-
β1 stimulation, the cells were fixed in methanol at −20 °C
for 15 min, washed with PBS, and then blocked using
0.2 % gelatin in PBS for 1 h. Cells were incubated overnight
at 4 °C in a humidified chamber with a goat antibody
against HA-probe (F-7, Santa Cruz Biotechnology) and a
rabbit antibody against caveolin-1 (N-20, Santa Cruz Bio-
technology) at 1:100 dilutions. After extensive washing, the
cells were incubated with Rhodamine-conjugated donkey
anti-goat antibody and FITC-conjugated mouse anti-rabbit
antibody at a 1:50 dilution for 1 h. Images were acquired
using a Leica TCS SP confocal microscope (Leica Micro-
systems Ltd., Heidelberg, Germany). The measurements of
the colocalization rate were analyzed using a Leica Appli-
cation Suite.
Separation of lipid-raft and non-lipid raft microdomains
of plasma membranes by sucrose density gradient
ultracentrifugation
Sucrose density gradient analysis was performed at 4 °C
as described previously [26]. In brief, cells were grown
to near-confluence in 100-mm dishes (5–10 × 106 cells
per dish). Cells were incubated with BetA (5 μg/mL) or
cholesterol (25 μg/mL) at 37 °C for 4 h. After 2 washes
with ice-cold PBS, the cells were scraped in 0.85 mL of
500 mM sodium carbonate (pH 11). Homogenization
was performed with 10 strokes of a tightfitting Dounce
homogenizer, followed by three 15-s bursts of an ultra-
sonic disintegrator (Qsonica, Newtown, CT, USA) to dis-
rupt the cell membranes. The homogenates were
adjusted to 45 % sucrose by adding 0.85 mL of 90 %
sucrose in 25 mM 2-(N-morpholino) ethanesulfonic acid
(pH 6.5) and 0.15 M NaCl (MBS), and placed at the bot-
tom of an ultracentrifuge tube. A discontinuous sucrose
gradient was generated by overlaying 1.7 mL of 35 %
sucrose and of 5 % sucrose in MBS on top of the 45 %
sucrose solution, and it was subsequently centrifuged at
40 000 rpm for 16–20 h in a P50S2 rotor (Himac, Tokyo,
Japan). Ten 0.5-mL fractions were collected from the
top of the tube, and a portion of each fraction was ana-
lyzed through SDS-PAGE, followed by Western blot
analysis using antibodies to TβRI (ALK-5), TβRII, TfR-1,
EEA-1, flotillin-2, EGFR, and caveolin-1. The relative
amounts of TβRI, TβRII, TfR-1, and caveolin-1 on the
blot were quantified through densitometry. The protein
recovery and localization of caveolin-1, flotillin-2, and
TfR-1 (fractions 4 to 5 and 8 to 10, respectively) did not
change significantly with any of the treatment protocols
(Fig. 8). An HA-tagged TβRII (TβRII-HA) construct was
(See figure on previous page.)
Fig. 2 BetA enhances the transcriptional response stimulated by TGF-β in Mv1Lu cells. Cells stably expressing the PAI-1 luciferase reporter plasmid
exhibited a 6-fold increase of the luciferase activity after stimulation with 100 pM TGF-β and the TGF-β-stimulated luciferase activity was enhanced
by BetA in a concentration-dependent manner (a) and (b). However, the BetA-enhanced TGF-β-stimulated PAI-1 luciferase activity was diminished
in the presence of cholesterol (b). Cells transiently transfected with the fibronectin (c) and collagen (d) luciferase reporter plasmids were treated
with 100 pM TGF-β and increasing concentrations of BetA and/or cholesterol. BetA also enhanced the TGF-β-stimulated luciferase activity driven
by the promoters of fibronectin (c) and collagen (d). The presence of cholesterol inhibited these BetA-enhanced luciferase activities (b, c, and d).
The data bar represents the mean ± S.D. ** and * indicate the significant different between cells treated with or without BetA (a), or lower than
that in cells treated without cholesterol in the same concentration of BetA group (b, c, and d) (*: P < 0.05, **: P < 0.01)
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transfected at a concentration of 0.5 μg/mL in the indi-
cated experiments.
MTT viability assay
The effect of BetA on TGF-β-induced growth inhibition
was determined using an MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazoliumbromide) assay. In brief,
the cells were plated at 1× 104 cells per well in 150 μL of
a culture medium containing 1 % FCS and the desired
concentrations of BetA, before they were diluted with
the culture media to achieve final concentrations ran-
ging from 0.5 to 5 μg/mL. The EtOH concentration
remained within the maximum permissible concentra-
tion of 0.01 % in both the control and treated samples.
After pretreatment with BetA, the cells were treated
with TGF-β, and incubation continued for 30 h at 37 °C
in a humidified incubator, after which cell viability was
determined. Afterward, 50 μL of MTT (4 μg/mL in PBS
stock, diluted to a working strength of 1 μg/mL with the
media) was added to each well and incubated for 2 h.
After the medium was carefully removed, 0.1 mL of
DMSO was added to each well, and the plates were
shaken. Absorbance was recorded on a microplate
reader, at a wavelength of 570 nm. The effect of BetA on
(See figure on previous page.)
Fig. 3 BetA enhances the TGF-β response downstream of ALK-5 in Mv1Lu cells. Cells stably expressing the PAI-1 luciferase promoter were transiently
transfected with caALK-5 or pcDNA3.1 (as a control). These transfected cells exhibited a potent luciferase activity in the absence of exogenously added
TGF-β. BetA appeared to enhance caALK-5-stimulated PAI-1 (a and b), fibronectin (c), and collagen (d) promoter luciferase expression in a con-
centration-dependent manner. Cholesterol treatment suppressed the BetA-enhanced luciferase activity. The data bar represents the mean ± SD from four
different analyses. * and **Significantly higher than that in cells treated without BetA (a) or lower than that in cells treated without cholesterol
(b, c, and d) (*: P< 0.05, **: P< 0.01)
A
B
Fig. 4 BetA enhances TGF-β-induced Smad2 phosphorylation and nuclear translocation in Mv1Lu cells. Cells were pretreated with BetA, for 0, 0.5,
1, 2, 4, and 6 h, and then further incubated with 100 pM TGF-β for 30 min. The P-Smad2 and total Smad2 levels in the cell lysates were analyzed
by immunoblotting. The relative level of P-Smad2 (P-Smad2/Smad2) was estimated. A representation of 2 analyses is shown (a). The quantitative
analysis of the immunoblots is shown (b). The relative level of P-Smad2 in cells treated only with TGF-β was taken as 100 % of TGF-β-stimulated
Smad2 phosphorylation. The data from three different analyses represents the mean ± SD. **Significantly higher than that in cells treated with
TGF-β alone (P < 0.01)
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growth inhibition was assessed as the percentage of cell
viability, where the vehicle-treated cells were considered
100 % viable.
Statistical analysis
The data represent the means ± standard deviation (SD).
Group means were compared by one-way ANOVA (ana-
lysis of variance), followed by Tukey’s procedure for mul-
tiple comparisons if necessary, using statistical software
program SPSS ver. 17.0 for Windows (SPSS, Chicago, IL,
USA). In all comparisons, a value of p < 0.01 was consid-
ered to indicate a statistically significant difference.
Results
BetA enhances TGF-β-induced transcriptional responsive
The Mv1Lu cells were selected to examine the effect of
BetA on TGF-β signaling. The Mv1Lu cell is a model cell
line for TGF-β investigation, and exhibits a strong dosage-
dependent responsiveness to TGF-β, as determined by
Mv1Lu cells stably expressing the luciferase reporter gene
driven by the PAI-1 promoter. TGF-β (100 pM) induced
luciferase activity by approximately 6-fold in Mv1Lu cells
(Fig. 2a). The TGF-β-dependent luciferase activity was en-
hanced by BetA treatment in a concentration-dependent
manner, start with an approximate 20 % increase in
A
B
Fig. 5 BetA increases the TGF-β-induced nuclear translocation of Smad2 in Mv1Lu cells. After 1 h of incubation of cells with 5 μg/mL BetA followed
by 30 min of treatment with 20 pM TGF-β, the cells were fixed, subjected to immunofluorescence staining with primary antibodies against Smad2 as
well as secondary antibodies linked to FITC, and mounted with a DAPI-containing medium. FITC fluorescence represents P-Smad2 staining (A, panels
a-e), whereas the nuclei were subjected to DAPI staining (A, panels f-j). The nuclear/cytoplasm ratio of the Smad2 level was determined among 100
cells in 10 different fields, and were quantified using Image J (NIH, Bethesda, MD) (B). Values are expressed as the mean ± SD (n = 3). **The group of
BetA/ TGF-β co-treatment significantly higher than that in cells treated with TGF-β only (P < 0.01)
Chen et al. Journal of Biomedical Science  (2016) 23:30 Page 8 of 15
0.5 μg/mL BetA-treated cells, and reaching roughly 60 %
at 5 μg/mL of BetA (Fig. 2b). The BetA also enhanced the
TGF-β-induced transcriptional activation of fibronectin
and collagen, as determined by transient transfection with
the fibronectin and collagen luciferase promoter con-
structs (Fig. 2c and d, respectively). This study proposed
that BetA enhances TGF-β responsiveness by moving
TGF-β receptors out of the lipid raft microdomain in the
plasma membrane. To find supporting evidence of this
hypothesis, the cells were treated with 10 μg/mL or 20 μg/
mL of cholesterol, which has been reported as a critical
component of lipid raft microdomains. Our previous re-
ports have indicated that adding cholesterol to cultured
cells could induce recruitment of TGF-β receptors into
the lipid raft membrane microdomain and facilitate recep-
tor degradation [17, 18]. As shown in Fig. 2, cholesterol
prevented the BetA-enhanced transcriptional activation of
PAI-1, fibronectin, and collagen induced by TGF-β
(Fig. 2b, c, and d, respectively). Cholesterol and BetA did
not affect the basic reporter gene activity, indicating that
the induced TGF-β response was affected, not the lucifer-
ase activity or cellular activity itself. We did not observe
any cell death from treatment with either BetA or choles-
terol, as determined by MTT assay and trypan blue cell
exclusion assays (data not shown). To further assess
whether BetA acts on ligand binding and subsequent ac-
tive receptor complex formation or on downstream TGF-
β signaling, Mv1Lu cells were transiently transfected with
caALK-5, which resulted in an 8-fold induction of PAI-1
promoter activity without TGF-β stimulation (Fig. 3a).
The BetA enhanced caALK-5-stimulated transcriptional
activities, including PAI-1, fibronectin, and collagen
Fig. 6 BetA promotes TGF-β-induced fibronectin expression. Cells were incubated with 1.25 μg/mL and 2.5 μg/mL of BetA, and then treated with
100 pM TGF-β for 48 h. Whole-cell extracts were prepared and analyzed by Western blot analysis using an antibody against fibronectin (top). The
quantitative data from three analyses is shown as mean ± SD (bottom). **The group of BetA/TGF-β co-treatment significantly higher than that in
cells treated with TGF-β only (P < 0.01)
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(Fig. 3b, c, and d, respectively), in a concentration-
dependent manner. Cholesterol treatment suppressed the
BetA-specific luciferase activities exclusively, not the basal
luciferase activities induced by caALK-5. This result im-
plies that BetA and cholesterol affect the components of
the TGF-β receptor-Smad signaling pathway, rather than
altering ligand binding to TGF-β receptors.
BetA enhances TGF-β-induced Smad2 phosphorylation
and nuclear translocation
Because cholesterol is a critical structural component of
lipid rafts and caveolae [27, 28] and shares a similar
chemical structure with BetA, treatment of cells with
BetA may modulate TGF-β-stimulated signaling and cel-
lular responses by altering the structure and function of
lipid rafts/caveolae. To test the effect of BetA on TGF-β-
induced signaling, we determined the effect of BetA
treatment on TGF-β-stimulated Smad2 phosphorylation
and nuclear translocation, both of which are key signal-
ing events leading to TGF-β responsiveness [16, 29, 30].
As shown in Fig. 4a and b, BetA effectively enhanced
Smad2 phosphorylation stimulated by TGF-β in a time-
dependent manner in Mv1Lu cells. After 1 h of BetA
pretreatment, Smad2 phosphorylation increased by
75 %. At 2 h of pretreatment, BetA enhanced Smad2
phosphorylation by over 100 %. To determine the effect
of BetA on Smad2 nuclear translocation, we performed
immunofluorescent staining using the anti-Smad2/3
antibody and nuclear 4′,6-diamidine-2-phenylindole
(DAPI) staining. As shown in Fig. 5A, BetA enhanced
TGF-β-induced Smad2 nuclear translocation (Fig. 5Ad
versus Fig. 5Ac). After counting the cells that underwent
Smad2 nuclear localization from 3 separate experiments,
we found that TGF-β-induced Smad2 nuclear transloca-
tion in all of the treated cells, whereas BetA enhanced
Smad2 nuclear translocation in 70 ± 5 % of these cells
(Fig. 5B). In the experiments with BetA alone and the
vehicle (0.01 % EtOH), the cells did not exhibit any
nuclear translocation (Figs. 5Aa and Ab, respectively).
Overall, these results imply that BetA treatment en-
hances TGF-β1-induced signaling.
TGF-β1-induced fibronectin expression is promoted by
BetA
One biological activity of TGF-β is the transcriptional
activation of gene coding for extracellular matrix (ECM)
proteins, which is a crucial event in wound healing, tis-
sue repair, and cancer progression in adult tissue [31,
32]. During prolonged treatment, TGF-β successively in-
duces epithelial-mesenchymal transition differentiation
with an increased expression of ECM proteins, including
fibronectin in epithelial cells [33, 34]. This transcrip-
tional activation is mediated by the Smad2/3 signaling
pathway. To define the effect of BetA on TGF-β respon-
siveness, we determined that of BetA on TGF-β-induced
fibronectin expression in cells by using an ECL system
for western blotting. As shown in Fig. 6, the treatment
of Mv1Lu cells with BetA increased TGF-β-induced
fibronectin expression: at 1.25 μg/mL, BetA enhanced
fibronectin expression by approximately 95 % compared
with TGF-β alone (lane 3 versus lane 2) in Mv1Lu cells.
At 2.5 μg/mL of BetA treatment, we found a slight
Fig. 7 BetA enhances TGF-β-induced cell death in Mv1Lu cells. Cells were pretreated with BetA for 4 h and stimulated with 20 pM of TGF-β for
30 h. The MTT (cell viability) assay showed that BetA enhanced TGF-β-induced cell death in a concentration-dependent manner after 30 h of
exposure to BetA. Data represents the mean ± SD (n = 3). **Significantly lower than that in cells treated with TGF-β alone (P < 0.01)
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decrease in fibronectin expression compared with
1.25 μg/mL of BetA treatment, which may be due to
other effects from long-term BetA treatment.
TGF-β-induced Mv1Lu cell growth inhibition is enhanced
by BetA
Another prominent biological activity of TGF-β is the
growth inhibition of numerous cell types [12, 16, 30,
35–37]. If BetA enhances TGF-β responsiveness, it
should augment TGF-β growth inhibition, which is also
mediated by the Smad2/3 signaling pathway. To verify
this hypothesis, we pretreated Mv1Lu cells with increas-
ing concentrations (as indicated) of BetA at 37 °C for
4 h, and then further incubated them with 20 pM TGF-
β at 37 °C for 30 h. In order to show the TGF-β-induced
growth inhibition enhanced by BetA, we used a low
concentration (20 pM) of TGF-β in these experiments.
In the absence of BetA, 20 pM of TGF-β inhibited
Mv1Lu cell growth by approximately 10 % (the first
closed circle on the left side in Fig. 7). In the presence of
BetA (0.6 to 5 μg/mL), TGF-β1-induced growth inhib-
ition increased by 40 % (the closed circles in Fig. 7). In
this study, none of the BetA concentrations used af-
fected cell growth and viability significantly (the open
circles in Fig. 7). The control was treated with 0.01 %
EtOH without TGF-β (the first open circle from the left
side in Fig. 7).
BetA increases TGF-β receptor accumulation in the
non-caveolae microdomain
We previously reported that TGF-β responsiveness is deter-
mined by the localization of TβR-I and TβR-II in the lipid
Fig. 8 Sucrose density gradient analysis of TβR-II (a, b) and TβR-II-HA (c, d) in the plasma membrane of Mv1Lu cells and Mv1Lu cells transiently
transfected with TβR-II-HA plasmid after treatment with BetA. Mv1Lu cells (a, b) or Mv1Lu cells transiently expressing TβR-II-HA (c, d) were pretreated with
or without 5 μg/mL of BetA at 37 °C for 4 h. The cell lysates from these treated cells were subjected to sucrose density gradient ultracentrifugation. The
sucrose gradient fractions were then analyzed by Western blot analysis using anti-TβR-II, anti-HA probe, anti-EGFR, anti-flotillin-2, anti-TfR-1,
and anti-caveolin-1 antibodies. The arrow indicates the locations of TβR-II, TfR-1, and caveolin-1. Fractions 4 and 5 contained lipid rafts/caveolae,
whereas fractions 8, 9, and 10 were non-lipid raft fractions. Treatment with BetA alone did not affect the total amounts of TβR-II, TβR-II-HA, and other
cell proteins (Additional file 1, Fig. 1). The * symbol indicates the increased amount of TβR-II in the fraction compared with that of the untreated
control. The # indicates the decreased amount of TβR-II in the fraction compared with that of the untreated control. BetA treatment induced TβR-II
(or TβR-II-HA) translocation from lipid rafts/caveolae to non-lipid raft microdomains. However, BetA treatment did not alter EGFR distribution between
lipid rafts/caveolae and non-lipid raft microdomains. The level of TβR-II (a) or TβR-II-HA (c) in lipid rafts/caveolae and non-lipid raft microdomains was
determined. The quantitative data from three analyses is shown (b, d) as the mean ± SD (n = 3). *, ** Significantly lower or higher than that in cells
treated without BetA (control) (*: P < 0.05, **: P < 0.01) (b, d)
Chen et al. Journal of Biomedical Science  (2016) 23:30 Page 11 of 15
raft/caveolae and non-caveolae microdomains of the
plasma membranes [17–19, 26]. To test the effect of BetA
on the plasma microdomain localization of TGF-β recep-
tors, we analyzed the lipid raft and non-lipid raft
localization of TβR-II in the plasma membrane of untreated
cells or cells treated with BetA (5 μg/mL) by conducting
sucrose density gradient ultracentrifugation analysis
followed by western blotting. As shown in Fig. 8a, TβR-II
was present in both the non-caveolae (fractions 8 to 10)
and lipid raft/caveolae fractions (4 and 5), which contained
transferrin receptor 1 (TfR-1) and caveolin-1, respectively.
After BetA treatment, TβR-II was found to be enriched in
the non-caveolae fractions (8 and 9) of the plasma mem-
brane in Mv1Lu cells compared with the same fractions
before BetA treatment (Fig. 8, BetA versus control). Treat-
ment with nystatin, a cholesterol-depleting agent, also
induced TβR-II translocation from the lipid raft/caveolae to
non-caveolae microdomain. We confirmed that BetA plays
a similar role to nystatin in TGF-β receptor translocation.
Both BetA and nystatin moved the TGF-β receptor from
fractions 4 and 5 (lipid raft) to fractions 8 to 10 (non-lipid
raft) (Fig. 8a BetA versus nystatin). As shown in Fig. 8c,
Mv1Lu cells transiently expressing HA-tagged TβR-II were
incubated in control media or media containing 5 μg/mL
of BetA, and were processed for sucrose gradient fraction-
ation and western blotting with the anti-HA probe
antibody. The BetA treatment induced TβR-II-HA trans-
location from lipid raft to non-lipid raft microdomains. To
test whether BetA changes the membrane localization of
other types of growth factor receptors, we examined EGF
receptor localization in BetA-treated cells. The BetA treat-
ment did not alter the membrane localization of EGF
receptors (Fig. 8a). To further test BetA-induced TGF-β
receptor translocation in the plasma membrane, Mv1Lu
cells transiently expressing TβR-II-HA were treated with or
without BetA, and were analyzed trough immunofluores-
cence microscopy by using antibodies against HA-probe












Fig. 9 The immunofluorescence localization of TβR-II-HA and caveolin-1 in Mv1Lu cells treated with and without BetA. The Mv1Lu cells transiently express-
ing TβR-II-HA were treated with or without 5 μg/mL of BetA at 37 °C for 1 h. The cells were then fixed with cold methanol and incubated with a mouse
antibody against HA (panels a and b) and a rabbit antibody against caveolin-1 (panels b and e), followed by incubation with Rhodamine-conjugated
donkey anti-mouse antibody or FITC-conjugated goat anti-rabbit antibody. Fluorescence in cells was examined using a confocal microscope: Bar, 20 μm.
The white arrows indicate the colocalization of TβR-II-HA and caveolin-1 at the cell surface and endocytic vesicle (panel c, enlarged picture in lower right
corner.) before BetA treatment. (panel f, enlarged picture in upper right corner.) BetA treatment reduces the colocalization of TβR-II-HA and caveolin-1
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experiment, TβR-II-HA (depicted in red) and caveolin-1
(green) were colocalized and accumulated in lipid rafts
(Fig. 9c). After 30 min of BetA treatment, BetA reduced the
colocalization of TβR-II-HA and caveolin-1 (Fig. 9f). Com-
bined with the findings shown in Figs. 8 and 9, these results
imply that cell treatment with BetA and nystatin increased
the accumulation of TβR-II in non-caveolae microdo-
mains, and presumably increased endosomal signaling
[18, 26, 38], resulting in enhanced TGF-β responsiveness.
Discussion and conclusion
Triterpenoids are studied extensively for their potential use
as anticancer and antifibrotic agents [39–45], and BetA is
one of the most promising compounds in this class. Several
proteins and pathways are clearly targeted by BetA, but
none of these individual targets provide a satisfactory and
comprehensive view of the overall mechanism. The BetA
compound has been shown to inhibit aminopeptidase N,
an enzyme involved in the regulation of angiogenesis that is
overexpressed in several cancers [46, 47]. Moreover, one
study demonstrated that BetA blocks the catalytic activity
of topoisomerase I by abrogating the interaction of the en-
zyme and the DNA substrate [48]. Another important tar-
get is the NFκB pathway, a pro-inflammatory and pro-
survival node in which a transcription factor regulates
many cell cycle, differentiation, and apoptosis genes; this
pathway is constitutively active in many human cancers
[49, 50]. The BetA suppresses NFκB activation by inhibiting
IκBα kinase and p65 phosphorylation [51]. Although
PPARγ, aminopeptidase N, IκBα Kinase, and NFκB are the
direct targets of BetA, they still cannot account for all of its
known biological activities. Because BetA is similar to
cholesterol in structure, it is tempting to speculate that
BetA may be intercalated into lipid rafts and might modu-
late their membrane fluidity like other cholesterol deriva-
tives [23]. However, BetA-induced apoptosis is not
mediated by the Fas receptor, which is activated when
membrane fluidity is increased after cellular exposure to
methyl-β-cyclodextrin [52]. Suh et al. and Ji et al. have
reported that synthesized triterpenoids synergize with
TGF-β to induce the expression of TGFβ receptors as well
as the activity of the TGF-β-responsive plasminogen
activator inhibitor-1 (PAI-1) promoter, prolong Smad
phosphorylation and signaling, and activate the
promoters of activin and BMP reporter constructs
[53, 54]. However, despite all of these observations,
an immediate, direct molecular target of triterpenoids
in the TGF-β network has yet to be identified [55].
Di Guglielmo et al. [38] and Chen et al. [18, 19, 26]
have demonstrated that TGF-β responsiveness is
Fig. 10 A model for the BetA effect on TGF-β partitioning between lipid rafts/caveolae- and clathrin-mediated endocytosis. Two major TβR-I-TβR-II
complexes (Complexes I and II) are present on the cell surface. Complexes I and II are localized mainly in the non-lipid raft and lipid
raft/caveolae microdomains, respectively, of the plasma membrane. BetA treatment results in decreased formation, or the disruption of
the lipid raft, and subsequently moves TβR-I-TβR-II to non-lipid raft microdomains where TGF-β binding to the receptors induces Smad2
signaling, leading to cellular responses
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determined by TGF-β receptor partitioning between
lipid raft/caveolae-mediated and clathrin-mediated
endocytosis. Lipid raft/caveolae-mediated endocytosis
facilitates TGF-β degradation, thereby suppressing
TGF-β responsiveness. By contrast, clathrin-mediated
endocytosis results in Smad2/3-dependent endosomal
signaling, thus promoting TGF-β responsiveness.
Based on the dominance model for the signal that
controls TGF-β partitioning between the 2 distinct
endocytosis pathways [18, 19, 26, 36], to the best of
our knowledge, this study is the first to propose that
BetA increased TGF-β responsiveness through lipid raft
disruption and by pushing the TGF-β-TGF-β receptor com-
plex into the non-lipid raft microdomain in the plasma
membrane. Several lines of evidence presented herein indi-
cate that BetA is a TGF-β receptor activator that can effect-
ively enhance (Smad2/3-dependent) TGF-β responsiveness
in Mv1Lu cells: BetA treatment (1) enhances TGF-β-
induced transcriptional activation such as PAI-1, fibronec-
tin, and the collagen promoter, and these “BetA-specific”
activations are antagonized by cholesterol treatment; (2)
enhances TGF-β-induced signaling such as Smad2 phos-
phorylation and nuclear translocation; (3) increases
TGF-β-induced fibronectin expression in Mv1Lu cells;
(4) augments TGF-β-induced growth inhibition in
Mv1Lu cells; and (5) most important, the effect of BetA
on TGF-β responsiveness is rapid and coordinates with
BetA-induced TGF-β receptor translocation from lipid
raft/caveolae to non-caveolae on the plasma membrane.
The effect starts from 30 min after the incubation of
BetA-treated cells, and reaches its maximum effect at
2 h (unpublished results). In this study, we demon-
strated that BetA treatment increases the accumulation
of TβR-I and TβR-II to non-lipid rafts/non-caveolae (as
Complex I) (Fig. 10), resulting in enhanced TGF-β
responsiveness. The depletion of cholesterol from the
plasma membrane by cholesterol-depleting agents (e.g.,
nystatin) leads to a decreased formation or destabilization
of lipid rafts/caveolae, thereby also increasing the
localization of TβR-I and TβR-II (as Complex I) in non-
lipid raft microdomains (Fig. 8a). It is possible that a
number of these activities are mediated by their ability to
affect the structure and function of lipid rafts/caveolae,
which are known to modulate signaling mediated by G
protein-coupled receptors, receptor tyrosine kinases
(EGFR), TGF-β receptors (TβR-I and TβR-II), and possibly
others [21, 26, 38, 56–58]. However, in the present study,
EGFR membrane microdomain localization remained
unchanged after BetA treatment. These results implicate
the specificity of BetA treatment in TGF-β responsiveness.
In conclusion, this is the first report to show that BetA
augments TGF-β signaling by shifting TGF-β receptors
from the lipid raft/caveolae to non-caveolae microdomain
in the plasma membrane.
Additional file
Additional file 1: Figure S1. The treatment of BetA does not change
the levels of TβR-II, TβR-II, and caveolin-1 in Mv1Lu cells. Figure S2.
SB431542 inhibits BetA-enhanced TGF-β-induced fibronectin expression
in Mv1Lu cells. (PDF 325 kb)
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